Baxter International Inc. (BAX)
Largest Insider Buys in Sector
BAX Stock Price History Chart
BAX Stock Performance
About Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical …
Insider Activity of Baxter International Inc.
Over the last 12 months, insiders at Baxter International Inc. have bought $0 and sold $2.62M worth of Baxter International Inc. stock.
On average, over the past 5 years, insiders at Baxter International Inc. have bought $1.61M and sold $11.13M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 19,560 shares for transaction amount of $1.61M was made by Martin Sean (SVP and General Counsel) on 2020‑03‑30.
List of Insider Buy and Sell Transactions, Baxter International Inc.
| 2024-03-01 | Sale | EVP, Chief HR Officer | 64,488 0.0126% | $40.61 | $2.62M | -10.12% | ||
| 2023-02-21 | Sale | SVP, Chief Quality Officer | 3,813 0.0008% | $40.50 | $154,427 | -1.16% | ||
| 2023-01-17 | Sale | SVP, Human Resources | 59,477 0.0118% | $44.70 | $2.66M | -8.76% | ||
| 2022-04-05 | Sale | 1,215 0.0002% | $76.63 | $93,105 | -26.35% | |||
| 2022-04-05 | Sale | 2,827 0.0006% | $75.76 | $214,174 | -26.35% | |||
| 2022-04-01 | Sale | 1,005 0.0002% | $77.68 | $78,068 | -27.92% | |||
| 2022-03-01 | Sale | director | 1,005 0.0002% | $84.82 | $85,244 | -30.01% | ||
| 2022-02-28 | Sale | SVP, CAO and Controller | 2,500 0.0005% | $85.50 | $213,757 | -30.68% | ||
| 2022-02-14 | Sale | SVP, Human Resources | 54,143 0.0107% | $85.02 | $4.6M | -29.87% | ||
| 2022-02-02 | Sale | director | 1,680 0.0003% | $84.53 | $142,010 | -28.82% | ||
| 2022-02-01 | Sale | director | 1,005 0.0002% | $85.59 | $86,018 | -27.60% | ||
| 2021-11-01 | Sale | SVP and General Counsel | 21,450 0.0043% | $79.57 | $1.71M | -6.90% | ||
| 2021-08-02 | Sale | SVP and General Counsel | 19,800 0.004% | $77.26 | $1.53M | +2.66% | ||
| 2021-04-12 | Sale | SVP, President, APAC | 21,998 0.0044% | $84.79 | $1.87M | -3.28% | ||
| 2021-04-05 | Sale | director | 9,980 0.0013% | $57.91 | $577,942 | -3.92% | ||
| 2021-04-05 | Sale | director | 9,980 0.002% | $84.56 | $843,909 | -3.92% | ||
| 2020-11-02 | Sale | SVP and General Counsel | 94,002 0.0184% | $78.67 | $7.4M | +3.34% | ||
| 2020-09-14 | Sale | director | 620 <0.0001% | $57.42 | $35,604 | -2.99% | ||
| 2020-09-03 | Sale | SVP, Chief Quality Officer | 5,314 0.0011% | $85.87 | $456,313 | -3.32% | ||
| 2020-08-03 | Sale | director | 29,798 0.0061% | $86.41 | $2.57M | -1.96% |
Insider Historical Profitability
| Baxter Healthcare SA | 10 percent owner | 2603295 0.5099% | $33.36 | 1 | 0 | <0.0001% |
| KRAEMER HARRY M JANSEN JR | Chairman and | 694556 0.136% | $33.36 | 1 | 0 | +11.65% |
| PARKINSON ROBERT L JR | Chairman of the Board & CEO | 465485 0.0912% | $33.36 | 2 | 6 | +5.36% |
| JEHARAJAH NEVILLE J | Corporate Vice President | 127603 0.025% | $33.36 | 1 | 0 | +8.11% |
| GREISCH JOHN J | Corporate Vice President | 90419 0.0177% | $33.36 | 2 | 2 | +1.81% |
Institutional Investor Ownership
| BlackRock | $2.61B | 11.96 | 60.96M | +2.15% | +$54.92M | 0.06 | |
| The Vanguard Group | $2.55B | 11.73 | 59.75M | -0.68% | -$17.42M | 0.05 | |
| Dodge & Cox | $1.18B | 5.4 | 27.5M | +0.44% | +$5.15M | 0.68 | |
| Voya Investment Management | $1.04B | 4.79 | 24.41M | +0.56% | +$5.78M | 3.58 | |
| State Street | $918.2M | 4.19 | 21.34M | -0.07% | -$618,256.08 | 0.04 |